sparfloxacin has been researched along with pefloxacin in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (44.44) | 18.2507 |
| 2000's | 9 (33.33) | 29.6817 |
| 2010's | 6 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Baroni, M; Cecchetti, V; Cianchetta, G; Cruciani, G; Mannhold, R | 1 |
| Appelbaum, PC; Bhawsar, SB; Bozdogan, B; de Souza, NJ; Desai, VN; Deshpande, PK; Gupte, SV; Hooper, DC; Jacobs, MR; Jha, R; Khorakiwala, HF; Patel, MV; Shetty, N; Shukla, MC; Strahilevitz, J; Yeole, RD | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Bremont, S; Charavay, F; Courvalin, P; Goarant, C; Le Hello, S; O'Connor, O; Page, S; Vernel-Pauillac, F | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chhasatia, MR; Gandhi, DS; Patel, MN | 1 |
| Avdeef, A; Sun, N; Tam, KY; Tsinman, O | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Cheng, XW; Fan, YL; Feng, LS; Wu, JB; Zhang, FZ | 1 |
| Bergogne-Bérézin, E; Joly-Guillou, ML | 1 |
| Gelber, RH; Iranmanesh, A; Murray, L; Siu, P; Tsang, M | 1 |
| Carbon, C; Cochereau, I; Marrakchi-Benjaafar, S; Pocidalo, JJ | 1 |
| Baron, MH; Chenon, MT; Coupry, C; Lecomte, S; Moreau, NJ | 1 |
| Croizé, J; Le Noc, D; Le Noc, P | 1 |
| Bauchet, J; Cochereau-Massin, I; Faurisson, F; Marrakchi-Benjaafar, S; Pocidalo, JJ; Saleh-Mghir, A; Vallee, E; Vallois, JM | 1 |
| Iakovlev, SV; Iakovlev, VP; Izotova, GN | 1 |
| Belmatoug, N; Bleton, R; Carbon, C; Crémieux, AC; Garry, L; Manteau, M; Massias, L; Mazière, B; Mghir, AS; Sales, N | 1 |
| Bergogne-Bérézin, E; Houot, S; Joly-Guillou, ML; Moreau, NJ | 1 |
| Hoogkamp-Korstanje, JA | 1 |
| Baumann-Wilschke, I; Förster, C; Rücker, M; Shakibaei, M; Stahlmann, R; Vormann, J | 1 |
| Acar, JF; Goldstein, FW; Kitzis, MD; Miegi, M | 1 |
| Chen, X; Hua, H; Ji, C; Lin, X; Liu, Y; Tang, S; Yue, Z | 1 |
| Gandhi, DS; Parmar, PA; Patel, MN | 1 |
| Betlejewska-Kielak, K; Biernacka, J; Grudzień, M; Kłosińska-Szmurło, E; Mazurek, AP; Pluciński, FA | 1 |
2 review(s) available for sparfloxacin and pefloxacin
| Article | Year |
|---|---|
Fluoroquinolone derivatives and their anti-tubercular activities.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis | 2018 |
[Pharmacokinetics of fluoroquinolones in patients with renal insufficiency].
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Ofloxacin; Pefloxacin; Quinolones; Renal Insufficiency | 1995 |
25 other study(ies) available for sparfloxacin and pefloxacin
| Article | Year |
|---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
Topics: Anti-Bacterial Agents; Enterococcus faecalis; Escherichia coli; Models, Molecular; Pseudomonas aeruginosa; Quantitative Structure-Activity Relationship; Quinolones; Staphylococcus aureus; Thermodynamics | 2004 |
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Mutation; Prodrugs; Quinolizines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Vancomycin Resistance | 2005 |
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
Topics: Amino Acid Substitution; Base Sequence; DNA Gyrase; DNA Mutational Analysis; DNA Primers; DNA Probes; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Humans; Nucleic Acid Denaturation; Point Mutation; Polymerase Chain Reaction; Streptococcus pneumoniae; Thermodynamics | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Interaction of drug based binuclear mixed-ligand complexes with DNA.
Topics: Anti-Bacterial Agents; Bacteria; Binding Sites; Ciprofloxacin; Cobalt; DNA, Bacterial; Ligands; Magnetic Resonance Spectroscopy; Magnetics; Mass Spectrometry; Microbial Sensitivity Tests; Molecular Structure; Oxidation-Reduction; Spectrophotometry, Infrared; Structure-Activity Relationship; Temperature; Viscosity | 2009 |
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Topics: Caco-2 Cells; Cell Membrane Permeability; Humans; Hydrogen-Ion Concentration; Membranes, Artificial; Molecular Structure; Pharmaceutical Preparations | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
In-vitro activity of sparfloxacin, pefloxacin, ciprofloxacin and temafloxacin against clinical isolates of Acinetobacter spp.
Topics: Acinetobacter; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Pefloxacin; Quinolones | 1992 |
Activities of various quinolone antibiotics against Mycobacterium leprae in infected mice.
Topics: Animals; Anti-Infective Agents; Female; Fluoroquinolones; Leprosy; Mice; Mice, Inbred BALB C; Mycobacterium leprae; Pefloxacin; Quinolones | 1992 |
Systemic prophylaxis of experimental staphylococcal endophthalmitis: comparative efficacy of sparfloxacin, pefloxacin, imipenem, vancomycin, and amikacin.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Eye; Eye Infections, Bacterial; Female; Fluoroquinolones; Imipenem; Pefloxacin; Quinolones; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 1995 |
Effect of magnesium complexation by fluoroquinolones on their antibacterial properties.
Topics: Anti-Infective Agents; Bacteria; Fluoroquinolones; Magnesium; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Pefloxacin; Quinolones | 1994 |
[Compared antibacterial activity of a new fluoroquinolone, sparfloxacin (AT 4140, RP 64206) and four other fluoroquinolones against 332 strains of enteropathogen bacteria].
Topics: Anti-Infective Agents; Campylobacter jejuni; Ciprofloxacin; Dose-Response Relationship, Drug; Escherichia coli; Fluoroquinolones; Helicobacter pylori; Humans; In Vitro Techniques; Ofloxacin; Pefloxacin; Quinolones; Salmonella; Shigella; Vibrio cholerae; Yersinia enterocolitica | 1993 |
Efficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitis.
Topics: Animals; Anti-Infective Agents; Endophthalmitis; Eye; Fluoroquinolones; Half-Life; Injections; Injections, Intramuscular; Pefloxacin; Quinolones; Rabbits; Staphylococcal Infections; Vitreous Body | 1993 |
Efficacy of sparfloxacin and autoradiographic diffusion pattern of [14C]Sparfloxacin in experimental Staphylococcus aureus joint prosthesis infection.
Topics: Animals; Anti-Infective Agents; Autoradiography; Bone and Bones; Diffusion; Fluoroquinolones; Joint Prosthesis; Microbial Sensitivity Tests; Pefloxacin; Prosthesis-Related Infections; Quinolones; Rabbits; Staphylococcal Infections | 1996 |
Characterisation of DNA gyrase and measurement of drug accumulation in clinical isolates of Acinetobacter baumannii resistant to fluoroquinolones.
Topics: Acinetobacter; Anti-Infective Agents; Ciprofloxacin; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Microbial Sensitivity Tests; Pefloxacin; Quinolones | 1996 |
In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Pefloxacin; Quinolones; Respiratory Tract Infections | 1997 |
Effects of fluoroquinolones and magnesium deficiency in murine limb bud cultures.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Embryo, Mammalian; Embryonic and Fetal Development; Extremities; Fleroxacin; Fluoroquinolones; Magnesium Deficiency; Mice; Microscopy, Electron; Ofloxacin; Pefloxacin; Quinolones | 1998 |
In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis.
Topics: Anti-Infective Agents; beta-Lactamases; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Ofloxacin; Pefloxacin | 1999 |
[Determination of 16 quinolone residues in animal tissues using high performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry].
Topics: Animals; Chromatography, High Pressure Liquid; Ciprofloxacin; Enoxacin; Enrofloxacin; Fluoroquinolones; Norfloxacin; Ofloxacin; Pefloxacin; Quinolones; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization | 2007 |
Third generation fluoroquinolones antibacterial drug based mixed-ligand Cu(II) complexes: structure, antibacterial activity, superoxide dismutase activity and DNA-interaction approach.
Topics: 2,2'-Dipyridyl; Aldehydes; Anti-Infective Agents; Bacteria; Copper; DNA; Electrophoresis, Agar Gel; Fluoroquinolones; Ligands; Microbial Sensitivity Tests; Organometallic Compounds; Pefloxacin; Superoxide Dismutase; Thiophenes | 2011 |
Experimental and theoretical studies on the molecular properties of ciprofloxacin, norfloxacin, pefloxacin, sparfloxacin, and gatifloxacin in determining bioavailability.
Topics: Biological Availability; Buffers; Ciprofloxacin; Fluoroquinolones; Gastrointestinal Absorption; Gatifloxacin; Hydrogen-Ion Concentration; Models, Molecular; Molecular Conformation; Norfloxacin; Octanols; Pefloxacin; Phosphates; Solvents; Static Electricity; Thermodynamics | 2014 |